At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 187 enrolled
Drug / intervention
Upadacitinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis
In Brief
A Phase 2 clinical trial evaluating Upadacitinib and Placebo for Ankylosing Spondylitis (AS). Completed, enrolled 187 participants across 101 sites in 21 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis (AS) who have had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (NSAIDs) or intolerance to or a contraindication for NSAIDs, and who are naïve to biologic disease-modifying anti-rheumatic drugs (bDMARD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis (AS)
CountriesAustralia, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Netherlands, New Zealand, Poland, Portugal, South Korea, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartOct 2017
Primary CompletionJan 2019
Study CompletionFeb 2022
TodayJul 2026
First PostedJun 7, 2017
Enrollment StartOct 24, 2017
Primary CompletionJan 21, 2019
Study CompletionFeb 17, 2022
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.1 years ago
Interventions
Upadacitinibdrug
Tablet
Placebodrug
Tablet